Skip to main content
OpenTrials
Completed

NCT Number: NCT05486897

Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy

White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA). WMH tend to show a peri-basal ganglia pattern in HA, whereas a multiple subcortical spots pattern can be observed in CAA. Periventricular WMH (PVWMH) have been reported to be posterior predominant using a semiautomated segmentation method and logarithmic transformation, not used in daily clinical practice. In these studies including CAA patients, patients initially presented with haemorrhage-related symptoms. In another study analysing PVWMH and cerebral amyloid evidence in patients with mild cognitive impairment, frontal PVWMH burden was associated with high uptake on florbetapir-PET whereas parietal and occipital PVWMH burden was associated with low CSF-amyloid-beta.

The aim of this study is the descriptive comparative analysis of the distribution of PVWMH between CAA and HA patients with radiological tools available in daily practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cerebral Amyloid Angiopathy Amyloidosis Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebral Arterial Diseases Cerebrovascular Disorders Hypertensive Arteriopathy Intracranial Arterial Diseases Metabolic Diseases Nervous System Diseases Nutritional and Metabolic Diseases Proteostasis Deficiencies Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nîmes

Nîmes, 30029, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022.

Exclusion criteria

CAA and HA patients, treated at the CHU of Nîmes between January 2015 and March 2022, not objecting to the use of their health data

Treatment and study plan

None, pure observational study

Other

None, pure observational study

Primary outcomes

  1. Distribution of PVWMH

    Time frame: Base line, Day 0

    Maximal distance between the outer PVWMH border and the border of the lateral ventricle (on the axis oriented at 90° to the border of the ventricle)

  2. Distribution of PVWMH - total PVWMH extent.

    Time frame: Base line, Day 0

    The sum of the PVWMH measurements around the four ventricles horns (i.e. bilateral anterior and posteriors horns) resulted in total PVWMH extent.

  3. Corpus callosum (CC) WMH

    Time frame: Base line, Day 0

    Distance between the border of the third ventricle and the outer border of the WMH on the rostro-caudal axis, resulting in anterior and posterior CC-PVWMH extent measurements.

  4. Corpus callosum (CC) WMH - total CC-PVWMH extent.

    Time frame: Base line, Day 0

    The sum of the anterior and posterior CC-PVWMH measurements resulted in the total CC-PVWMH extent.

  5. Ratios

    Time frame: base line, day 0

    Calcul of posterior/anterior ratios for both the PVWMH and CC-PVWMH

  6. Anterior PVWMH

    Time frame: Base line, Day 0

    Comparison of anterior PVWMH between CAA group and HA group.

  7. Posterior PVWMH

    Time frame: Base line, Day 0

    Comparison of posterior PVWMH between CAA group and HA group.

  8. Total PVWMH

    Time frame: Base line, Day 0

    Comparison of total PVWMH between CAA group and HA group.

  9. Posterior/anterior PVWMH ratio

    Time frame: Base line, Day 0

    Comparison of the posterior/anterior PVWMH ratio between CAA and HA groups.

  10. anterior CC-PVWMH

    Time frame: Base line, Day 0

    Comparison of anterior CC-PVWMH between CAA group and HA group.

  11. Posterior CC-PVWMH

    Time frame: Base line, Day 0

    Comparison of posterior CC-PVWMH between CAA group and HA group.

  12. Total PVWMH and posterior/anterior CC-PVWMH ratio

    Time frame: Base line, Day 0

    Comparison of total PVWMH and posterior/anterior CC-PVWMH ratio between CAA group and HA group.

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Acronym: PVWMH

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 4, 2022
Registry last updated
Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.